Altea Therapeutics Expands its Product Development Capabilities with the Appointment of Directors of Clinical R&D, Pharmaceutical Sciences and Product Feasibility.Business Editors/Health/Medical Writers BIOWIRE2K TUCKER, Ga.--(BUSINESS WIRE)--June 7, 2004 Altea Therapeutics announced today the appointment of three new Directors from the pharmaceutical industry as it broadens the leadership of its product development programs. The Company's lead clinical products are a daily insulin skin patch skin patch, transdermal patch, or transdermal delivery system, adhesive patch used to deliver a controlled dose of a drug through the skin over a period of time. for treating individuals with diabetes, and hydromorphone skin patches for the controlled management of acute and chronic pain. Edda Gomez-Panzani, M.D. has joined the Company as Director of Clinical R&D and Head of Medical Affairs. As a former Medical Director for Procter & Gamble Pharmaceuticals she provided medical leadership to multi-functional U.S. and international study teams and was also responsible for Medical Safety. Her experience in drug development includes diverse therapeutic areas such as Pain/Migraine, Gastrointestinal Diseases gastrointestinal disease, n an abnormal state or function of the GI system. , Diabetes, Women's Health Women's Health Definition Women's health is the effect of gender on disease and health that encompasses a broad range of biological and psychosocial issues. Care, Dermatology dermatology (dûrmətŏl`əjē), branch of medicine concerned with diagnosis and treatment of diseases and disorders of the skin. and Respiratory. Dr. Gomez-Panzani holds an M.D. degree from the National Autonomous University of Mexico The National Autonomous University of Mexico (Spanish: , abbreviated UNAM) is a large public university in Mexico. It was founded on September 21 1551 as the Real y Pontificia Universidad de México . Frank Tagliaferri, Ph.D. is appointed Director of Pharmaceutical Sciences, responsible for product formulation, (bio)analysis, immunology and animal biological studies. Frank Tagliaferri is experienced in the design and analysis of novel delivery systems for both small molecules and biopharmaceuticals. He was most recently at NaPro Biotherapeutics as Director of Preclinical R&D. Dr. Tagliaferri holds a Ph.D. in Organic Chemistry from the University of Virginia. Ross Durland, Ph.D. becomes Director of Product Feasibility, responsible for leading the Company's experimental program to define product development candidates for the Company. Ross Durland was previously at Chromos You may be looking for:
In welcoming his new colleagues, Dr. David Enscore, the Senior Vice President for Product R&D at Altea Therapeutics stated that "we are delighted to announce the expansion of the Altea Therapeutics product development management team. Our new colleagues bring the broad leadership experience and capabilities necessary both to move our products into advanced stages of development and to help build a robust and differentiated product pipeline." About Altea Therapeutics Altea Therapeutics is a private Company developing innovative medicines in collaboration with the pharmaceutical and biotechnology industry. The Company uses its proprietary PassPort(TM) system to deliver protein and peptide drugs, small-molecule drugs, genes and vaccines from a skin patch to improve therapeutic utility and eliminate the need for invasive and painful needle injections. The Company is currently conducting Phase 1 clinical trials phase 1 clinical trial Phase 1 study. See Phase study. in the U.S. for AT1391, a daily skin patch to achieve continuous basal levels of insulin for people with diabetes, and Phase 1 clinical trials for AT1022 and AT2022, hydromorphone skin patches designed to provide rapid and sustained delivery of a potent opioid opioid /opi·oid/ (o´pe-oid) 1. any synthetic narcotic that has opiate-like activities but is not derived from opium. 2. any of a group of naturally occurring peptides, e.g. for the management of acute and chronic pain. Founded in 1998, Altea Therapeutics completed its Series B equity financing Equity Financing The act of raising money for company activities by selling common or preferred stock to individual or institutional investors. In return for the money paid, shareholders receive ownership interests in the corporation. of $17 million in November 2002 with Domain Associates, Venrock Associates and vSpring Capital vSpring Capital is an early-stage venture capital firm located in Salt Lake City, Utah. The fund currently manages approximately $200M and investing out of its second fund. as new investors. Please visit www.alteatherapeutics.com for further information. NOTE: PassPort(TM) is a trademark of Altea Therapeutics Corporation. Any other trademarks referred to belong to their respective owners. The statements in this press release regarding the products of Altea Therapeutics in development, product development plans, and projected financial results, are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, Altea Therapeutics ability to complete the design, development, and manufacturing process development of its products, manufacture and commercialize its products, obtain product and manufacturing approvals from regulatory agencies, manage its growth and expenses, finance its activities and operations, as well as marketplace acceptance of Altea Therapeutics products. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion